ATE474224T1 - Verfahren zur identifizierung von hemmstoffverbindungen der freisetzung von beta- amyloidpeptid (bap) - Google Patents

Verfahren zur identifizierung von hemmstoffverbindungen der freisetzung von beta- amyloidpeptid (bap)

Info

Publication number
ATE474224T1
ATE474224T1 AT02079139T AT02079139T ATE474224T1 AT E474224 T1 ATE474224 T1 AT E474224T1 AT 02079139 T AT02079139 T AT 02079139T AT 02079139 T AT02079139 T AT 02079139T AT E474224 T1 ATE474224 T1 AT E474224T1
Authority
AT
Austria
Prior art keywords
beta
amyloid peptide
bap
inhibitor compounds
release inhibitor
Prior art date
Application number
AT02079139T
Other languages
English (en)
Inventor
Dale B Schenk
Peter A Seubert
Carmen Vigo-Pelfrey
Dennis J Selkoe
Michael G Schlossmacher
Original Assignee
Elan Pharm Inc
Brigham & Womens Hospital
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25510753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE474224(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharm Inc, Brigham & Womens Hospital, Lilly Co Eli filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE474224T1 publication Critical patent/ATE474224T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
AT02079139T 1992-10-26 1993-09-01 Verfahren zur identifizierung von hemmstoffverbindungen der freisetzung von beta- amyloidpeptid (bap) ATE474224T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96597292A 1992-10-26 1992-10-26

Publications (1)

Publication Number Publication Date
ATE474224T1 true ATE474224T1 (de) 2010-07-15

Family

ID=25510753

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02079139T ATE474224T1 (de) 1992-10-26 1993-09-01 Verfahren zur identifizierung von hemmstoffverbindungen der freisetzung von beta- amyloidpeptid (bap)
AT93921300T ATE247282T1 (de) 1992-10-26 1993-09-01 Verfahren zur identifizierung von hemmstoffe der produktion des beta-amyloidpeptids

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT93921300T ATE247282T1 (de) 1992-10-26 1993-09-01 Verfahren zur identifizierung von hemmstoffe der produktion des beta-amyloidpeptids

Country Status (9)

Country Link
EP (2) EP1298436B1 (de)
JP (2) JP3553592B2 (de)
AT (2) ATE474224T1 (de)
CA (1) CA2105903C (de)
DE (3) DE69334337D1 (de)
DK (2) DK0667959T3 (de)
ES (2) ES2346852T3 (de)
PT (2) PT1298436E (de)
WO (1) WO1994010569A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671093B2 (en) * 1992-01-07 1996-08-15 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US5484940A (en) * 1994-11-28 1996-01-16 Grant; Francine S. Substituted 3-indolyl-5-pyrazolone compounds
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
US6117901A (en) 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
US6642261B2 (en) 1997-11-21 2003-11-04 Athena Neurosciences, Inc. N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6096782A (en) 1996-11-22 2000-08-01 Athena Neurosciences, Inc. N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
IL135564A0 (en) * 1997-12-22 2001-05-20 Elan Pharm Inc POLYCYCLIC α-AMINO-ɛ-CAPROLACTAMS AND RELATED COMPOUNDS
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
AU3474100A (en) * 1999-01-25 2000-08-07 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
DE1257584T1 (de) * 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002324787A1 (en) 2001-08-10 2003-02-24 University Of South Florida Modulation of angiogenesis by a-beta peptides
PT1416965E (pt) * 2001-08-17 2008-04-01 Lilly Co Eli Método de ensaio para a doença de alzheimer
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP4220548B2 (ja) 2003-06-05 2009-02-04 エラン ファーマシューティカルズ，インコーポレイテッド アシル化されたアミノ酸・アミジルピラゾール、および関連化合物
EP1739425B1 (de) 2004-03-31 2009-09-09 AnGes MG, Inc. Testverfahren zur identifizierung eines kandidatenarzneistoffs
US20080220445A1 (en) 2004-10-01 2008-09-11 Takeda Pharmaceutical Company Limited Method of Screening Transmembrane Enzyme Inhibitory Substance
US20090123952A1 (en) * 2004-11-12 2009-05-14 Pfizer, Inc. Method of Measuring Amyloid-Beta Peptides
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
JP2009516654A (ja) 2005-11-10 2009-04-23 ロスキャンプ リサーチ， エルエルシー Ａ−ベータペプチドによる血管新生の調節
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8986657B2 (en) 2009-07-31 2015-03-24 The General Hospital Corporation Methods and system for detecting soluble amyloid-β
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
CN102955014B (zh) * 2012-10-19 2014-12-31 上海吉尔多肽有限公司 一种Aβ-淀粉样多肽1-42纯度的检测方法
EP3341725B1 (de) * 2015-08-25 2021-08-18 Prothena Biosciences Limited Verfahren zur detektion von phosphoryliertem alpha-synuklein
CN105153273A (zh) * 2015-08-25 2015-12-16 苏州强耀生物科技有限公司 一种制备β-淀粉样多肽1-40纯品的方法
CN109696550B (zh) * 2017-10-20 2022-08-26 成都蓝瑙生物技术有限公司 用于脑中风的发光elisa体液样品稳定化用水溶液

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
US5221607A (en) * 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
ES2217250T3 (es) * 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
WO1992000521A1 (en) * 1990-06-29 1992-01-09 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
BE1003316A5 (fr) * 1990-11-27 1992-02-25 Will L F & Cie Sa Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation.
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein

Also Published As

Publication number Publication date
EP0667959A1 (de) 1995-08-23
PT1298436E (pt) 2010-10-21
AU4844493A (en) 1994-05-24
AU687747B2 (en) 1998-03-05
JP3694303B2 (ja) 2005-09-14
JP3553592B2 (ja) 2004-08-11
JPH08502587A (ja) 1996-03-19
ES2203620T3 (es) 2004-04-16
DK1298436T3 (da) 2010-10-25
ATE247282T1 (de) 2003-08-15
EP1298436B1 (de) 2010-07-14
EP0667959B1 (de) 2003-08-13
CA2105903C (en) 2011-11-01
DE667959T1 (de) 2000-04-20
EP1298436A2 (de) 2003-04-02
CA2105903A1 (en) 1994-04-27
PT667959E (pt) 2003-12-31
JP2004121251A (ja) 2004-04-22
ES2346852T3 (es) 2010-10-21
WO1994010569A1 (en) 1994-05-11
EP0667959A4 (de) 1998-07-08
DK0667959T3 (da) 2003-12-08
DE69333144D1 (de) 2003-09-18
EP1298436A3 (de) 2003-07-09
DE69333144T2 (de) 2004-05-19
DE69334337D1 (de) 2010-08-26

Similar Documents

Publication Publication Date Title
ATE474224T1 (de) Verfahren zur identifizierung von hemmstoffverbindungen der freisetzung von beta- amyloidpeptid (bap)
Hultén et al. Dynamics in serum of the inflammatory markers serum amyloid A (SAA), haptoglobin, fibrinogen and α2‐globulins during induced noninfectious arthritis in the horse
Dowdle, EB, Mustard, P. & Eales d-Aminolaevulinic acid synthetase activity in normal and porphyric human livers
ATE396644T1 (de) Vorrichtung zum detektieren eines analyten und zur verabreichung einer therapeutischen substanz
ATE78175T1 (de) Magnetische fluessigkeitszusammensetzungen.
CA2088587A1 (en) In vivo measurement of oxygen concentration levels
AU2392692A (en) Method and kit for measuring endogenous cytokines
ATE122467T1 (de) Verfahren zur detektion von knochen- und anderen bindegewebeerkrankungen bei menschen und tieren.
Groothuis et al. Brain tumors and the blood—brain barrier
Jeste et al. A biochemical study of tardive dyskinesia in young male patients
FR2666096B1 (fr) Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu.
Jepson et al. Decreased in vivo and in vitro erythropoiesis induced by plasma of ten patients with thymoma, lymphosarcoma, or idiopathic erythroblastopenia
ATE117090T1 (de) Verfahren zur diagnose von tumoren.
EP0308926A2 (de) Methode zur Bestimmung des Verhaltens von Medikamenten in Lebewesen
Neill et al. A possible source of error in the diagnosis of phaeochromocytoma
Arbuthnott et al. Identification of grafted neurons with fluorescent-labelled microbeads
Kagen et al. Embryonic synthesis of myoglobin in vivo estimated by radioimmunoassay
Wogan et al. Biological monitoring of environmental toxic chemicals.
Piasecki et al. Continuous intraoperative monitoring of hepatic blood perfusion using a noninvasive surface electrode
Schwartz et al. Quantitative differentiation of minute amounts of the coproporphyrin isomers (I and III) based on fluorescence behavior
RU2136152C1 (ru) Способ определения естественной резистентности организма птиц
DE19602764C1 (de) Verfahren zur Bestimmung von Bromelain-Gehalten im Blutplasma
Tomokuni et al. The effect of exposing men and animals to lead on the pH activity curves of hepatic and erythrocyte δ-aminolaevulinate dehydratase
BABRAHAM PROCEEDINGS OF THE PHYSIOLOGICAL SOCIETY
BROCKEMEYER A measurement of the efficiency of ointment bases in releasing a local anesthetic by using a pain threshold method

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1298436

Country of ref document: EP